Overview

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

Status:
Not yet recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, study designed to evaluate the preliminary efficacy, safety and pharmacokinetics of RC108 in patients with c-Me-positive advanced digestive system malignancies.
Phase:
Phase 2
Details
Lead Sponsor:
RemeGen Co., Ltd.